Literature DB >> 17626255

Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection.

Davide Rossi1, Silvia Franceschetti, Daniela Capello, Lorenzo De Paoli, Monia Lunghi, Annarita Conconi, Gianluca Gaidano.   

Abstract

Lymphocytosis associated with viral infection is generally polyclonal or oligoclonal. In this article, we describe a case of transient monoclonal CD8+/CD57+ T-cell lymphocytosis with large granular lymphocyte (LGL) morphology occurring after primary CMV infection and review cases of virus-associated monoclonal CD8+ T-cell expansions reported in the literature. Several clinical features shared by virus-associated monoclonal CD8+ T-cell expansions suggest the reactive nature of the lymphocytosis. Based on this, our case report and those reported in the literature support the notion that T-cell receptor clonality per se is not necessarily indicative of malignancy. These observations further corroborate the need for a close follow-up before assigning the diagnosis of LGL leukemia to individuals developing monoclonal CD8+ T-cell expansions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626255     DOI: 10.1002/ajh.20981

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  The small heat shock protein 27 is a key regulator of CD8+ CD57+ lymphocyte survival.

Authors:  Karen L Wood; Oliver H Voss; Qin Huang; Arti Parihar; Neeraj Mehta; Sanjay Batra; Andrea I Doseff
Journal:  J Immunol       Date:  2010-04-12       Impact factor: 5.422

Review 3.  Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Authors:  Kazuo Oshimi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

Review 4.  Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection.

Authors:  Núria Climent; Montserrat Plana
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

5.  [Clinical features and risk factors analyses of patients with T cell large granular lymphocytosis following allo-HSCT].

Authors:  F Zhao; Y Y Shi; G X Zhang; W H Zhai; A M Pang; Q L Ma; R L Zhang; J L Wei; Y Huang; D L Yang; Y He; E L Jiang; S Z Feng; M Z Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 6.  Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation.

Authors:  Karen L Wood; Homer L Twigg; Andrea I Doseff
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

7.  A case of secondary syphilis masquerading as cutaneous lymphoma.

Authors:  Kevin Nethers; Rafael E Mojica; Etan Marks; Robin Burger; Sadia Saeed; William Steffes
Journal:  JAAD Case Rep       Date:  2021-06-09

Review 8.  Large granular lymphocytosis after transplantation.

Authors:  Zhi-Yuan Qiu; Guang-Yu Tian; Zhao Zhang; Ye-Qing Zhang; Wei Xu; Jian-Yong Li
Journal:  Oncotarget       Date:  2017-09-18

9.  Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Authors:  Anna Lissina; James E McLaren; Mette Ilander; Emma I Andersson; Catherine S Lewis; Mathew Clement; Andrew Herman; Kristin Ladell; Sian Llewellyn-Lacey; Kelly L Miners; Emma Gostick; J Joseph Melenhorst; A John Barrett; David A Price; Satu Mustjoki; Linda Wooldridge
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.